The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Prodrugs for improving tumor targetability and efficiency
Open accessAbstract
As the mainstay in the treatment of various cancers for several decades, chemotherapy is successful but still faces challenges including non-selectivity and high toxicity. Improving the selectivity is therefore a critical step to improve the therapeutic efficacy of chemotherapy. Prodrug is one of the most promising approaches to increase the selectivity and efficacy of a chemotherapy drug. The classical prodrug approach is to improve the pharmaceutical properties (solubility, stability, permeability, irritation, distribution, etc.) via a simple chemical modification. This review will focus on various targeted prodrug designs that have been developed to increase the selectivity of chemotherapy drugs. Various tumor-targeting ligands, transporter-associated ligands, and polymers can be incorporated in a prodrug to enhance the tumor uptake. Prodrugs can also be activated by enzymes that are specifically expressed at a higher level in tumors, leading to a selective anti-tumor effect. This can be achieved by conjugating the enzyme to a tumor-specific antibody, or delivering a vector expressing the enzyme into tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Aptamers evolved from live cells as effective molecular probes for cancer study
Shangguan, D., Li, Y., Tang, Z., Cao, Z. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J., & Tan, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602615103 · Cited by 1,516
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Development of DNA aptamers using Cell-SELEX
Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M. B., & Tan, W. (2010) · Nature Protocols · doi:10.1038/nprot.2010.66 · Cited by 918
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Cited by
Biological Activity of Ionic Liquids and Their Application in Pharmaceutics and Medicine
Egorova, K. S., Gordeev, E. G., & Ananikov, V. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00562 · Cited by 1,649
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Disulfide-Cleavage-Triggered Chemosensors and Their Biological Applications
Lee, M. H., Yang, Z., Lim, C. W., Lee, Y. H., Dongbang, S., Kang, C., & Kim, J. S. (2013) · Chemical Reviews · doi:10.1021/cr300358b · Cited by 821
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Wen, H., Jung, H., & Li, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9814-9 · Cited by 574
Wu, X., Sun, X., Guo, Z., Tang, J., Shen, Y., James, T. D., Tian, H., & Zhu, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412380j · Cited by 539
Development and application of bond cleavage reactions in bioorthogonal chemistry
Li, J., & Chen, P. R. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2024 · Cited by 529
ROS‐Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy
Xu, X., Saw, P. E., Tao, W., Li, Y., Ji, X., Bhasin, S., Liu, Y., Ayyash, D., Rasmussen, J., Huo, M., et al. (2017) · Advanced Materials · doi:10.1002/adma.201700141 · Cited by 499
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 441
Lee, M. H., Han, J. H., Kwon, P.-S., Bhuniya, S., Kim, J. Y., Sessler, J. L., Kang, C., & Kim, J. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210065g · Cited by 408
Activity-Based Sensing and Theranostic Probes Based on Photoinduced Electron Transfer
Sun, W., Li, M., Fan, J., & Peng, X. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00340 · Cited by 364
Lee, M. H., Kim, J. Y., Han, J. H., Bhuniya, S., Sessler, J. L., Kang, C., & Kim, J. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303998y · Cited by 309
The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy
Han, H.-H., Wang, H.-M., Jangili, P., Li, M., Wu, L., Zang, Y., Sedgwick, A. C., Li, J., He, X.-P., James, T. D., et al. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00673a · Cited by 299
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kaniskan, H. Ü., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 297
Singh, R. K., Kumar, S., Prasad, D. N., & Bhardwaj, T. R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.001 · Cited by 282
Disulfide-Based Multifunctional Conjugates for Targeted Theranostic Drug Delivery
Lee, M. H., Sessler, J. L., & Kim, J. S. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00406 · Cited by 254
Cheng, Y., Huang, F., Min, X., Gao, P., Zhang, T., Li, X., Liu, B., Hong, Y., Lou, X., & Xia, F. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02833 · Cited by 94
Targeted Cancer Therapy with a 2-Deoxyglucose-Based Adriamycin Complex
Cao, J., Cui, S., Li, S., Du, C., Tian, J., Wan, S., Qian, Z., Gu, Y., Chen, W. R., & Wang, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2072 · Cited by 84
Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging
Park, J., Kim, S., Saw, P. E., Lee, I.-H., Yu, M. K., Kim, M., Lee, K., Kim, Y.-C., Jeong, Y. Y., & Jon, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.029 · Cited by 48
Metadata
- Authors
- Mahato, R., Tai, W., & Cheng, K.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 63
- Issue
- 8
- Pages
- 659-670
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1978556565
- Cited by
- 353
- References
- 100
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.